Last updated: July 31, 2026
Cleviprex, the brand name for clevidipine butyrate injectable emulsion, is an ultra-short-acting intravenous dihydropyridine calcium-channel blocker used to reduce blood pressure when oral therapy is not practical. The drug remains commercially relevant in perioperative and intensive-care settings because it can be rapidly titrated and discontinued. Its principal commercial risks are generic competition, hospital formulary substitution and the limited duration of intravenous antihypertensive treatment.
Cleviprex was approved by the U.S. Food and Drug Administration in 2008 under NDA 022268. Chiesi USA markets the product in the United States. FDA-approved labeling covers short-term blood-pressure reduction in adults, including patients undergoing cardiac surgery and those with severe hypertension where oral therapy is not feasible [1].
What is Cleviprex and how does clevidipine work?
Cleviprex contains clevidipine butyrate, an intravenous dihydropyridine calcium-channel blocker. It produces arterial vasodilation by inhibiting L-type calcium channels in vascular smooth muscle. The drug has a rapid onset and short offset because it is rapidly metabolized by blood and tissue esterases.
The formulation is a lipid emulsion supplied at 0.5 mg/mL. It is administered by continuous intravenous infusion and titrated according to blood-pressure response. The product is not intended for prolonged maintenance therapy when oral antihypertensive treatment is available [1].
Key product characteristics
| Attribute |
Cleviprex |
| Active ingredient |
Clevidipine butyrate |
| Dosage form |
Intravenous injectable emulsion |
| Strength |
0.5 mg/mL |
| Route |
Continuous intravenous infusion |
| Therapeutic class |
Dihydropyridine calcium-channel blocker |
| U.S. approval |
2008 |
| U.S. NDA |
022268 |
| Primary use |
Short-term blood-pressure reduction |
| Key settings |
Cardiac surgery, intensive care, perioperative hypertension |
| U.S. marketer |
Chiesi USA |
| Administration |
Titrated intravenous infusion |
| Major safety considerations |
Hypotension, reflex tachycardia, lipid-related restrictions, impaired lipid metabolism |
The lipid formulation creates additional manufacturing and handling requirements compared with conventional aqueous injectable products. The product is contraindicated in patients with defective lipid metabolism and in patients with severe aortic stenosis, according to the prescribing information [1].
What clinical trials supported Cleviprex approval?
Cleviprex’s clinical development program established rapid blood-pressure control in perioperative and severe-hypertension populations. The principal studies included the ESCAPE trials, the ECLIPSE trials and the VELOCITY study.
ESCAPE-1 and ESCAPE-2
ESCAPE-1 evaluated clevidipine in patients undergoing cardiac surgery who required preoperative blood-pressure reduction. ESCAPE-2 assessed patients with acute postoperative hypertension after cardiac surgery. Both studies evaluated the ability to achieve target blood pressure rapidly through titrated infusion.
The studies demonstrated that clevidipine could reduce blood pressure within minutes, with dose adjustment allowing clinicians to control the magnitude of the response. These studies supported the drug’s role in the perioperative setting.
ECLIPSE trials
The ECLIPSE program consisted of three randomized studies involving patients undergoing cardiac surgery. The trials compared clevidipine with commonly used intravenous antihypertensive agents, including nitroglycerin, sodium nitroprusside and nicardipine.
The program focused on perioperative blood-pressure control and safety outcomes. Clevidipine provided effective control, but the trials did not establish a broad mortality advantage over other short-acting intravenous agents. The commercial value of the ECLIPSE data is therefore concentrated in titratability, rapid offset and use in high-acuity hospital protocols rather than in a differentiated survival benefit.
VELOCITY study
VELOCITY evaluated clevidipine in patients with severe hypertension. The study used continuous infusion with titration to achieve prespecified blood-pressure targets. Results showed rapid reduction in systolic blood pressure and supported use in patients who require short-term intravenous treatment [2].
What is the current Cleviprex clinical-trial pipeline?
Cleviprex has no active late-stage development program comparable to a new molecular entity. The clinical-trial opportunity is largely post-approval and practice-oriented.
| Clinical area |
Development status |
Commercial relevance |
| Perioperative hypertension |
Established indication |
High |
| Cardiac-surgery blood-pressure control |
Established evidence base |
High |
| Acute severe hypertension |
Established use |
High |
| Stroke-related blood-pressure control |
Clinical use may occur by institutional protocol, but not a broad new Cleviprex indication |
Moderate |
| Pediatric hypertension |
Limited commercial opportunity and label constraints |
Low to moderate |
| Chronic hypertension |
Not a target market because treatment is intravenous and short term |
Low |
| Combination therapy |
No major standalone development program |
Low |
ClinicalTrials.gov and published literature have not established a new indication capable of materially expanding the addressable market. Future evidence generation is more likely to involve comparative effectiveness, intensive-care protocols, health-economic studies and hospital pathway optimization than a new registration program [3].
How effective is Cleviprex compared with nicardipine and other intravenous antihypertensives?
Cleviprex competes primarily with intravenous nicardipine, clevidipine’s closest pharmacologic substitute. Other alternatives include nitroprusside, nitroglycerin, labetalol and esmolol.
| Product |
Main advantage |
Main limitation |
| Cleviprex |
Very rapid titration and short offset |
Higher acquisition cost; lipid-emulsion handling |
| Intravenous nicardipine |
Broad hospital familiarity and generic availability |
Longer effective offset than clevidipine |
| Nitroprusside |
Potent, rapid vasodilation |
Cyanide and thiocyanate toxicity concerns with prolonged exposure |
| Nitroglycerin |
Useful when ischemia or preload reduction is relevant |
Less predictable arterial blood-pressure control |
| Labetalol |
Useful when heart-rate reduction is also desired |
Longer duration and less titratable response |
| Esmolol |
Rapid beta-blockade |
Does not provide the same arterial vasodilation profile |
Cleviprex’s strongest clinical differentiators are dose titration, short duration and rapid recovery after discontinuation. Its weaknesses are price, intravenous-only administration and the need to account for lipid exposure.
What is the FDA and Orange Book status of Cleviprex?
Cleviprex is an FDA-approved prescription injectable product listed under NDA 022268. The Orange Book is the principal source for identifying listed patents, therapeutic-equivalence evaluations and exclusivity information [4].
The drug’s original regulatory exclusivity has expired. Cleviprex therefore competes in a post-exclusivity environment in which generic manufacturers can seek approval through an abbreviated new drug application, provided they demonstrate the required pharmaceutical and bioequivalence characteristics.
Because Cleviprex is an injectable emulsion, generic approval can require more extensive formulation, analytical and manufacturing work than a simple aqueous injection. The reference product’s clinical history does not prevent generic entry, but formulation complexity can affect the number and timing of challengers.
What patents protect Cleviprex?
The core composition and formulation patent estate associated with Cleviprex has been subject to patent-expiration analysis in FDA and patent databases. The most commercially relevant protection has historically involved the clevidipine injectable emulsion, manufacturing processes and formulation characteristics rather than a long-term new-use patent strategy.
Cleviprex does not have the patent profile of a biologic with multiple interchangeable-product barriers. Its practical protection is more dependent on:
- The complexity of reproducing the lipid emulsion.
- Pharmaceutical equivalence requirements.
- Device, container and packaging compatibility.
- Manufacturing validation.
- Hospital purchasing relationships.
- Any remaining Orange Book-listed patents or regulatory exclusivity.
Patent expiration dates should be checked against the current Orange Book listing and relevant USPTO records before a launch, licensing or litigation decision. Patent status can change through delisting, terminal disclaimers, litigation settlements or updated expiration calculations [4,5].
When does Cleviprex lose exclusivity and face generic entry?
Cleviprex has already lost its original U.S. regulatory exclusivity. Generic entry risk is therefore active rather than remote. The timing of a specific generic launch depends on FDA approval, patent certifications, any Paragraph IV litigation and commercial readiness.
A generic applicant may file a Paragraph IV certification alleging that listed patents are invalid, unenforceable or not infringed. If the NDA holder files an infringement action within the statutory period, FDA approval may be subject to a 30-month stay, subject to court decisions and statutory exceptions [6].
Generic launch scenarios
| Scenario |
Market effect |
| No approved generic |
Chiesi retains most branded demand, but hospitals continue price negotiations |
| One approved generic |
Pricing pressure increases; large health systems may convert selected protocols |
| Multiple generics |
Cleviprex becomes a premium or restricted formulary product |
| Authorized generic or licensed alternative |
Faster price erosion with potentially greater supply reliability |
| Manufacturing disruption |
Brand may retain share despite price competition |
A first generic entrant could obtain a temporary commercial advantage depending on the filing history and exclusivity rights. The duration and scope of that advantage must be confirmed from the applicable ANDA and Orange Book records.
Which companies are challenging Cleviprex?
Publicly identifiable generic activity should be evaluated through FDA approvals, Orange Book records, ANDA litigation dockets and SEC filings. The existence of a patent certification or ANDA filing does not guarantee commercial launch.
The most relevant potential challengers are generic injectable manufacturers with lipid-emulsion capabilities, including large hospital-injectable suppliers and specialty manufacturers. Competitive assessment should focus on:
- FDA approval status for clevidipine injectable emulsion.
- Paragraph IV notices and district-court filings.
- Manufacturing-site inspections and supply capacity.
- Product presentation, vial or bottle configuration and stability data.
- Hospital contracting relationships.
No biosimilar pathway applies to Cleviprex because clevidipine is a chemically synthesized small molecule, not a biologic. The relevant threat is generic substitution, not biosimilar interchangeability.
What patent litigation and settlement issues affect Cleviprex?
Cleviprex-related litigation risk is primarily associated with ANDA patent challenges, formulation patents and potential infringement claims involving injectable-emulsion composition or manufacturing methods.
A Paragraph IV case can produce four commercial outcomes:
- Settlement with a delayed generic launch date.
- License allowing an agreed entry date.
- Litigation victory for the generic applicant.
- Litigation victory or injunction for the patent holder.
Any settlement involving a generic entrant can materially alter the market forecast. Important provisions include the entry date, authorized-generic restrictions, supply arrangements, launch rights, patent covenants and treatment of future formulations.
The absence of a widely publicized settlement does not eliminate risk. Injectable products can face litigation around patents that are narrower than the original active-ingredient protection but still relevant to the commercial formulation.
What is the Cleviprex market size and revenue exposure?
Chiesi does not provide a consistently separated public revenue line for Cleviprex in its corporate disclosures. The product’s market value must therefore be estimated from hospital use, intravenous antihypertensive spending, formulary penetration and generic competition rather than from a transparent segment-level revenue figure.
Cleviprex’s revenue exposure is concentrated in:
- U.S. cardiac-surgery centers.
- Intensive-care units.
- Hospitals with clevidipine-specific blood-pressure protocols.
- Facilities that value rapid titration and short offset.
- Patients unable to receive oral antihypertensive therapy.
The addressable patient population is smaller than that for chronic hypertension drugs. However, treatment episodes occur in high-acuity settings where hospitals may accept a price premium if clinicians perceive operational or safety benefits.
Market drivers
Positive drivers include:
- Growth in cardiac and major vascular surgery.
- Continued use of protocolized intensive-care blood-pressure management.
- Preference for short-acting, titratable agents.
- Drug shortages affecting competing intravenous products.
- Institutional demand for predictable blood-pressure control.
Negative drivers include:
- Generic clevidipine entry.
- Generic nicardipine substitution.
- Hospital purchasing pressure.
- Cost restrictions on lipid-based injectable products.
- Reduced use of intravenous therapy as oral therapy becomes feasible.
- Formulary standardization.
What is the Cleviprex market projection through 2030?
The most defensible projection is a scenario range rather than a single point estimate because public Cleviprex revenue disclosure is limited and generic-launch timing determines the slope of erosion.
| Scenario |
2025-2030 revenue trend |
Principal assumption |
| Premium-brand retention |
Low single-digit annual decline |
No major generic conversion and continued hospital preference |
| Managed erosion |
Mid- to high-single-digit annual decline |
One or more generics win contracts but Cleviprex retains specialist use |
| Rapid generic conversion |
Double-digit annual decline |
Multiple approved generics and broad therapeutic substitution |
| Supply-supported resilience |
Flat to modest decline |
Generic shortages, manufacturing problems or persistent clinical preference |
The base case is managed erosion. Cleviprex should retain a defensible niche because clevidipine offers a distinct titration profile and is embedded in cardiac-surgery and critical-care protocols. The brand is unlikely to sustain historical pricing after broad generic availability.
A reasonable commercial model assigns the brand a declining share of the clevidipine market, with value increasingly concentrated in hospitals that prioritize established supply, clinician familiarity and protocol continuity. Market expansion from new indications should not be assumed without new clinical and regulatory evidence.
How strong is the Cleviprex patent estate?
Cleviprex has moderate commercial protection and weak long-term exclusivity protection.
| Protection category |
Assessment |
| Active-ingredient protection |
Mature or expired |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Potentially relevant but vulnerable to design-around |
| Method-of-use protection |
Limited ability to block standard generic use |
| Manufacturing protection |
Can raise entry barriers but may not prevent approval |
| Trade secrets |
Relevant to process consistency and emulsion quality |
| Brand and hospital relationships |
Important after patent expiry |
| Biosimilar barrier |
Not applicable |
The strongest remaining barrier is likely technical execution: producing a stable, pharmaceutically equivalent injectable emulsion at commercial scale. That barrier can delay entry but rarely supports durable monopoly pricing once multiple manufacturers achieve approval.
What manufacturing and geographic barriers affect Cleviprex?
Cleviprex manufacturing requires control of emulsion droplet size, sterility, stability, container compatibility and lipid-related quality attributes. Generic manufacturers must also manage supply-chain risks involving sterile facilities, specialized filling equipment and release testing.
Geographic protection is strongest in jurisdictions where formulation patents remain enforceable or where regulatory approval is difficult. The U.S. market is the most commercially important because of the product’s established hospital use and Orange Book framework. European and other international markets may have different brand names, patent positions, reimbursement rules and generic-launch timelines.
A company evaluating licensing or acquisition should separate:
- U.S. Orange Book protection.
- European national patent status.
- Manufacturing-site ownership.
- Contract manufacturing dependence.
- Hospital distribution rights.
- Product shortages and backup supply.
- Regulatory approval status by country.
What is the investment outlook for Cleviprex?
Cleviprex is a mature hospital product rather than a growth-stage clinical asset. Its value is linked to cash-flow durability, manufacturing reliability and formulary retention.
The investment case is stronger where the owner controls:
- A differentiated sterile-emulsion manufacturing platform.
- Multiple hospital injectable products.
- Reliable U.S. supply.
- A generic-entry defense strategy.
- A recognized critical-care sales organization.
The investment case is weaker for an acquirer paying a growth multiple based on unproven indications or a broad chronic-hypertension opportunity. Cleviprex’s clinical utility is established, but the market is limited by intravenous administration and the availability of substitutable agents.
Key takeaways
- Cleviprex is an FDA-approved clevidipine injectable emulsion for short-term blood-pressure reduction.
- Its strongest clinical advantages are rapid titration, rapid onset and short offset.
- The evidence base includes ESCAPE, ECLIPSE and VELOCITY studies.
- The original regulatory exclusivity has expired.
- Generic entry, not biosimilar competition, is the central commercial risk.
- Formulation and sterile-manufacturing complexity may slow generic entry but are unlikely to preserve long-term monopoly pricing.
- The base-case outlook through 2030 is managed revenue erosion with continued niche use in cardiac surgery and intensive care.
- New-indication expansion should not be included in valuation without fresh clinical and regulatory evidence.
- Patent and litigation conclusions should be tied to the current Orange Book, USPTO records and ANDA docket activity.
FAQs about Cleviprex clinical trials, patents and market outlook
Is Cleviprex approved for chronic hypertension?
No. Cleviprex is intended for short-term intravenous blood-pressure reduction when oral therapy is not feasible or appropriate. It is not a chronic outpatient antihypertensive treatment.
Is clevidipine interchangeable with nicardipine?
The products have similar clinical roles but are not automatically interchangeable under an FDA therapeutic-equivalence designation. Hospital substitution depends on formulary policy, physician preference, clinical protocols and product availability.
Does Cleviprex have biosimilar competition?
No. Clevidipine is a small-molecule active ingredient. Competing products follow the generic-drug pathway rather than the biosimilar pathway.
Why is Cleviprex more expensive than some intravenous antihypertensives?
Cleviprex is supplied as a specialized lipid-based injectable emulsion and is marketed for high-acuity settings. Manufacturing, sterile filling, formulation control and hospital distribution contribute to cost. Generic competition can reduce the price differential.
What is the main commercial risk for Cleviprex after patent expiry?
The main risk is broad generic substitution by manufacturers capable of producing an equivalent clevidipine injectable emulsion. Hospital contracts and formulary decisions can accelerate market-share loss after the first credible generic launch.
References
-
U.S. Food and Drug Administration. (2023). Cleviprex (clevidipine butyrate) injectable emulsion prescribing information. Chiesi USA, Inc.
-
Pollack, C. V., Jr., Varon, J., Baskett, P. J. F., et al. (2009). Clevidipine, an intravenous dihydropyridine calcium antagonist, is safe and effective for the treatment of patients with acute severe hypertension. Blood Pressure, 18(4), 227-237.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov: Clevidipine clinical studies. ClinicalTrials.gov.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
United States Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search. USPTO.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. FDA.
